Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095158 Target Snapshot

Adrenergic receptor alpha-2 · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
495Compounds
230Assays
29Approved Drugs
549.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Adrenergic receptor alpha-2 shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P08913. Start with hypertension, then reuse UniProt P08913 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hypertension, then reuse UniProt P08913 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 5 linked drugs
Open source guide
Disease program
hypertension

Adrenergic receptor alpha-2 shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include BRIMONIDINE TARTRATE, CLONIDINE, CLONIDINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adrenergic receptor alpha-2 as ChEMBL target CHEMBL2095158, mapped to UniProt P08913. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Adrenergic receptor alpha-2
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2095158
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08913
Alpha-2A adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Adrenergic receptor alpha-2 is the right protein anchor across sources, using UniProt P08913 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hypertension is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameAdrenergic receptor alpha-2
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP08913
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAlpha-2A adrenergic receptor
UniProt AccessionP08913
Component TypeProtein
Sequence Length465 aa

Alpha-2A adrenergic receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Adrenergic receptor alpha-2, mapped to UniProt P08913. ChEMBL maps the protein component as Alpha-2A adrenergic receptor. Sequence length is 465 aa.

Mapped IDP08913
Review nameAdrenergic receptor alpha-2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Adrenergic receptor alpha-2 shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hypertension
5 linked drugs · 5 direct · 5 efficacy
Linked drugBRIMONIDINE TARTRATE
Linked drugCLONIDINE
Linked drugCLONIDINE HYDROCHLORIDE
Linked drugGUANFACINE HYDROCHLORIDE
Approved-linked Approved
attention deficit hyperactivity disorder
3 linked drugs · 3 direct · 3 efficacy
Linked drugCLONIDINE
Linked drugCLONIDINE HYDROCHLORIDE
Linked drugGUANFACINE HYDROCHLORIDE
Approved-linked Approved
cardiovascular disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugCELIPROLOL
Linked drugCLONIDINE
Approved-linked Approved
glaucoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugBRIMONIDINE TARTRATE
Linked drugCLONIDINE
Approved-linked Approved
insomnia
2 linked drugs · 2 direct · 2 efficacy
Linked drugESMIRTAZAPINE MALEATE
Linked drugMIRTAZAPINE
Approved-linked Approved
major depressive disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugIDAZOXAN
Linked drugMIRTAZAPINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hypertension because it currently carries approved-linked support. Linked drugs include BRIMONIDINE TARTRATE, CLONIDINE, CLONIDINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehypertension
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

29
Approved
7
Phase III
5
Phase II
Assay Mix

Activity Type Distribution

IC5077.0
KI340.0
EC5082.0
KD50.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL553231 10.85 IC50 0.014 Preclinical
CHEMBL557985 10.8 IC50 0.016 Preclinical
CHEMBL537830 10.47 IC50 0.034 Preclinical
CHEMBL10347 10.0 Ki 0.1 Preclinical
CHEMBL538801 9.92 IC50 0.12 Preclinical
CHEMBL62912 9.7 Kd 0.1995 Preclinical
CHEMBL279807 9.7 Kd 0.1995 Preclinical
CHEMBL50390 9.6 Ki 0.25 Preclinical
CHEMBL194837 9.6 IC50 0.25 Preclinical
CHEMBL554581 9.59 IC50 0.26 Preclinical
Distribution

pChEMBL Value Distribution

39
5.0
43
5.5
48
6.0
45
6.5
49
7.0
28
7.5
34
8.0
25
8.5
9
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

ZIPRASIDONE
CHEMBL708
Approved 2001
Properties Compare Identifier
QUETIAPINE
CHEMBL716
Approved 1997
Properties Compare Identifier
BRIMONIDINE
CHEMBL844
Approved 1996
Properties Compare Identifier
OLANZAPINE
CHEMBL715
Approved 1996
Properties Compare Identifier
RISPERIDONE
CHEMBL85
Approved 1993
Properties Compare Identifier
MOXONIDINE
CHEMBL19236
Approved 1991
Properties Compare Identifier
CLOZAPINE
CHEMBL42
Approved 1989
Properties Compare Identifier
APRACLONIDINE
CHEMBL647
Approved 1987
Properties Compare Identifier
RILMENIDINE
CHEMBL289480
Approved 1987
Properties Compare Identifier
OXYMETAZOLINE
CHEMBL762
Approved 1986
Properties Compare Identifier
PRAZOSIN
CHEMBL2
Approved 1976
Properties Compare Identifier
CLONIDINE
CHEMBL134
Approved 1974
Properties Compare Identifier
EPINEPHRINE
CHEMBL679
Approved 1965
Properties Compare Identifier
PHENTOLAMINE
CHEMBL597
Approved 1952
Properties Compare Identifier
PHENYLEPHRINE
CHEMBL1215
Approved 1952
Properties Compare Identifier
NOREPINEPHRINE
CHEMBL1437
Approved 1950
Properties Compare Identifier
Assay Landscape

Assay Landscape

230
Total Assays
261
Tested Compounds
2
Assay Types
Binding — 179 assays, 261 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 97 56 6.6
assay format 32 72 7.0
tissue-based format 26 35 7.1
cell-based format 14 14 7.9
cell membrane format 10 84 6.3
Functional — 51 assays, 79 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 20 22 5.6
tissue-based format 18 29 7.3
cell membrane format 11 24 4.9
cell-based format 2 4 6.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine